ORIC PHARMACEUTICALS, INC. (ORIC) Current Ratio
- Current ratio · latest quarter: Value 13.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.19× | Current assets / current liabilities. $273.69M ÷ $20.76M ≈ 13.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 273.69M USD | Assets, Current |
| Current obligations | 20.76M USD | Liabilities, Current |
| Cash and equivalents | 37.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 227.28M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.87M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $273.69M | $20.76M | $37.48M | $227.28M | (m) | (m) | $3.87M | (m) | 13.19× |
| 2026-03-31 | $290.23M | $17.77M | $56.40M | $225.54M | (m) | (m) | $2.90M | (m) | 16.33× |
| 2025-12-31 | $288.47M | $20.42M | $45.67M | $235.82M | (m) | (m) | $3.82M | (m) | 14.13× |
| 2025-09-30 | $295.59M | $20.18M | $49.67M | $237.47M | (m) | (m) | $2.90M | (m) | 14.65× |
| 2025-06-30 | $291.12M | $18.05M | $75.86M | $206.65M | (m) | (m) | $3.13M | (m) | 16.13× |
| 2025-03-31 | $211.43M | $17.62M | $49.33M | $154.39M | (m) | (m) | $5.16M | (m) | 12.00× |
| 2024-12-31 | $262.25M | $24.85M | $59.41M | $196.55M | (m) | (m) | $1.55M | (m) | 10.56× |
| 2024-09-30 | $279.43M | $21.25M | $44.23M | $228.14M | (m) | (m) | $4.25M | (m) | 13.15× |
| 2024-06-30 | $294.60M | $19.54M | $49.83M | $236.57M | (m) | (m) | $2.31M | (m) | 15.08× |
| 2024-03-31 | $324.08M | $15.21M | $56.36M | $260.42M | (m) | (m) | $2.99M | (m) | 21.31× |
| 2023-12-31 | $212.60M | $20.46M | $23.38M | $184.80M | (m) | (m) | $944.00K | (m) | 10.39× |
| 2023-09-30 | $232.24M | $18.94M | $26.24M | $201.06M | (m) | (m) | $3.74M | (m) | 12.26× |
| 2023-06-30 | $268.36M | $14.53M | $103.68M | $160.48M | (m) | (m) | $3.19M | (m) | 18.46× |
| 2023-03-31 | $193.16M | $14.87M | $58.99M | $130.64M | (m) | (m) | $1.93M | (m) | 12.99× |
| 2022-12-31 | $210.46M | $15.39M | $66.84M | $139.43M | (m) | (m) | $1.32M | (m) | 13.68× |
| 2022-09-30 | $198.69M | $13.28M | $29.08M | $164.58M | (m) | (m) | $1.53M | (m) | 14.96× |
| 2022-06-30 | $233.53M | $12.47M | $49.08M | $177.98M | (m) | (m) | $2.09M | (m) | 18.72× |
| 2022-03-31 | $239.09M | $11.82M | $112.64M | $121.98M | (m) | (m) | $888.00K | (m) | 20.23× |
| 2021-12-31 | $240.52M | $15.15M | $226.01M | $10.97M | (m) | (m) | $1.89M | (m) | 15.87× |
| 2021-09-30 | $292.85M | $11.90M | $241.13M | $48.39M | (m) | (m) | $419.00K | (m) | 24.60× |
| 2021-06-30 | $264.95M | $9.90M | $170.08M | $90.99M | (m) | (m) | $838.00K | (m) | 26.75× |
| 2021-03-31 | $280.10M | $7.68M | $104.21M | $173.93M | (m) | (m) | $606.00K | (m) | 36.49× |
| 2020-12-31 | $296.70M | $9.00M | $78.45M | $215.15M | (m) | (m) | $757.00K | (m) | 32.96× |
| 2020-09-30 | $189.06M | $6.93M | $62.03M | $124.58M | (m) | (m) | $1.60M | (m) | 27.29× |
| 2020-06-30 | $199.23M | $5.78M | $196.64M | (m) | (m) | (m) | $1.39M | (m) | 34.48× |
| 2020-03-31 | $80.23M | $4.78M | $79.44M | (m) | (m) | (m) | $770.00K | (m) | 16.78× |
| 2019-12-31 | $90.00M | $5.35M | $89.16M | (m) | (m) | (m) | $152.00K | (m) | 16.81× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |